OBAGI® ELASTIderm® Advanced Filler Concentrate
$115.00
ELASTIDERM® Advanced Filler Concentrate offers a highly effective topical approach inspired by popular needle-based procedures to visibly fill and smooth the appearance of fine lines and wrinkles.
- Clinically proven to visibly reduce the appearance of fine lines with a single application.*
- Provides an instant smoothing effect* with maximum results 8 hours after application.**
The precision tip applicator ensures targeted delivery, providing long-lasting benefits over time that address multiple areas of concern on the face, including forehead lines, brow lines, crow’s feet, laugh lines, and fine lines around the lips.
Out of stock
ELASTIDERM® Advanced Filler Concentrate offers a highly effective topical approach inspired by popular needle-based procedures to visibly fill and smooth the appearance of fine lines and wrinkles.
- Clinically proven to visibly reduce the appearance of fine lines with a single application.*
- Provides an instant smoothing effect* with maximum results 8 hours after application.**
The precision tip applicator ensures targeted delivery, providing long-lasting benefits over time that address multiple areas of concern on the face, including forehead lines, brow lines, crow’s feet, laugh lines, and fine lines around the lips.
Aqua/water/eau, dimethicone, glycerin, coco-caprylate/caprate, pentylene glycol, diglycerin, glyceryl stearate SE, microcrystalline cellulose, dimethicone/vinyl dimethicone crosspolymer, butyrospermum parkii (shea) butter, C10-18 triglycerides, hydrogenated olive oil stearyl esters, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, cetearyl alcohol, chlorphenesin, carbomer, trisodium ethylenediamine disuccinate, beta-glucan, caprylyl glycol, sodium hydroxide, polysorbate 60, sorbitan isostearate, acetyl hexapeptide-1.
Share your thoughts!
Let us know what you think...
Only logged in customers who have purchased this product may leave a review. Log in now
What others are saying
There are no contributions yet.